PLGA-particle vaccine carrying TLR3/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy

With emerging supremacy, cancer immunotherapy has evolved as a promising therapeutic modality compared to conventional antitumor therapies. Cancer immunotherapy composed of biodegradable poly(lactic-co-glycolic acid) (PLGA) particles containing antigens and toll-like receptor ligands induces vigorou...

Descripción completa

Detalles Bibliográficos
Autores principales: Koerner, Julia, Horvath, Dennis, Herrmann, Valerie L., MacKerracher, Anna, Gander, Bruno, Yagita, Hideo, Rohayem, Jacques, Groettrup, Marcus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8131648/
https://www.ncbi.nlm.nih.gov/pubmed/34006895
http://dx.doi.org/10.1038/s41467-021-23244-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8131648/
https://www.ncbi.nlm.nih.gov/pubmed/34006895
http://dx.doi.org/10.1038/s41467-021-23244-3

Ejemplares similares